Biotech traded higher again today, with gains concentrated around companies showing commercial traction, strategic validation, or visible pipeline catalysts. This episode covers Bayer’s ophthalmology acquisition, TG Therapeutics’ stronger Briumvi outlook, and Mirum’s rare disease expansion.

In today’s BioBrief:

• Bayer / Perfuse Therapeutics — Bayer agreed to acquire Perfuse Therapeutics for $300 million upfront and up to $2.45 billion including milestones, adding the Phase 2 ophthalmology asset PER-001 for glaucoma and diabetic retinopathy.
• TG Therapeutics / Briumvi — TG reported nearly $195 million in first-quarter U.S. Briumvi sales and raised full-year guidance to roughly $885–900 million, shifting the story further toward commercial execution and franchise durability. ...